Johnson & Johnson's Janssen: CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leukemia
June 24 2022 - 8:51AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on
Friday said the European Medicines Agency's Committee for Medicinal
Products for Human Use recommended expanded approval of the
blockbuster blood-cancer drug Imbruvica in certain patients with
chronic lymphocytic leukemia.
Janssen, which jointly develops and markets Imbruvica with
AbbVie Inc., said the recommendation covers the drug in an oral
fixed-duration combination with venetoclax for adults with
previously untreated chronic lymphocytic leukemia, a type of cancer
that starts from white blood cells in the bone marrow.
Janssen said the combination, if approved, would be the first
all-oral, once daily, fixed-duration combination regimen for
first-line treatment of the disease. The European Commission, which
generally follows the CHMP's advice, will make a final decision on
approval.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 24, 2022 08:36 ET (12:36 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Oct 2023 to Oct 2024